Cmax (pharmacology)

From Wikipedia, the free encyclopedia
  (Redirected from Peak (pharmacology))
Jump to: navigation, search

Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose. Cmax is the opposite of Cmin, which is the minimum (or trough) concentration that a drug achieves after dosing.[1]

Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed.[2]

After an intravenous administration, Cmax and Tmax are closely dependent on the experimental protocol, since the concentrations are always decreasing after the dose. But after oral administration,Cmax and Tmax are dependent on the extent, and the rate of drug absorption and the disposition profile of the drug. They could be used to characterize the properties of different formulations in the same subject.[3]

Short term drug side effects are most likely to occur at or near the Cmax whereas the therapeutic effect of drug with sustained duration of action usually occurs at concentrations slightly above the Cmin.

The Cmax is often measured in an effort to show bioequivalence between a generic and innovator drug product.[4] According to FDA, drug quality BA (bioavailability) and BE (bioequivalence) rely on pharmacokinetic measures such as AUC and Cmax that are reflective of systemic exposure.[5]

See also[edit]

Area under the curve (pharmacokinetics)

Cmin

References[edit]

  1. ^ Tracy TS (2004). "Pharmacokinetics". In Stitzel RE, Craig CF. Modern pharmacology with clinical applications. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 49. ISBN 0-7817-3762-1. 
  2. ^ http://www.lexjansen.com/phuse/2006/st/st03.pdf
  3. ^ Urso R, Blardi P, Giorgi G (March 2002). "A short introduction to pharmacokinetics". Eur Rev Med Pharmacol Sci 6 (2-3): 33–44. PMID 12708608. 
  4. ^ Midha KK, Rawson MJ, Hubbard JW (October 2005). "The bioequivalence of highly variable drugs and drug products". Int J Clin Pharmacol Ther 43 (10): 485–98. doi:10.5414/cpp43485. PMID 16240706. 
  5. ^ "Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations". FDA. Retrieved 13 December 2013.